News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Santhera Pharmaceuticals AG Mulls IPO To Finance Drug Development Pipeline
December 30, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Swiss biotech company Santhera Pharmaceuticals AG is looking at an initial public offering among several other options to finance its drug development pipeline, Chief Executive Klaus Schollmeier said.
Twitter
LinkedIn
Facebook
Email
Print
IPO
Europe
MORE ON THIS TOPIC
Gene therapy
AviadoBio Looks to China for Eye-Based Gene Therapy in $413M UgeneX Pact
October 10, 2025
·
2 min read
·
Tristan Manalac
Mergers & Acquisitions
Novo Strikes up to $5.2B Deal for Akero in Red-Hot MASH Space
October 9, 2025
·
2 min read
·
Annalee Armstrong
Mergers & acquisitions
Zenas Bets $2B+ in Autoimmune Agreement With Chinese Firm InnoCare
October 8, 2025
·
2 min read
·
Tristan Manalac
IPOs
UPDATE: MapLight Seeks $227M IPO for Neuropsych Portfolio
October 7, 2025
·
3 min read
·
Tristan Manalac
